Core Insights - EDAP TMS SA reported preliminary record sales of 11 Focal One Systems in the fourth quarter of 2024, indicating strong demand for its robotic HIFU technology [2] - The number of Focal One procedures in the U.S. grew by 30% year-over-year, reflecting the increasing adoption of this treatment for prostate cancer [2] - The company anticipates that the recent publication of the HIFI study in European Urology will further enhance awareness and adoption of the Focal One technology [2] Company Overview - EDAP TMS SA is recognized as a leader in robotic energy-based therapies, focusing on minimally invasive medical devices utilizing ultrasound technology [3] - The Focal One system is positioned as a leading prostate focal therapy, with potential applications extending beyond prostate cancer [3]
EDAP Announces Preliminary Record Fourth Quarter Focal One® System Sales and Record U.S. Procedures